Rearming the body’s immune system to fight cancer

We’re developing more precise and more accessible treatment alternatives for patients with solid cancers

The future of cancer treatment – combining stem cells and immunotherapy

Cartherics creates precisely-defined immunotherapy treatments to combat a variety of cancers. We combine the best components of immune targeting utilising gene editing and CAR technology to advance cell therapy to provide more diverse off-the-shelf treatments for patients. Our team has strong backgrounds in research, development, and product commercialisation. And we partner with leading commercial and academic groups with complementary technology to push the boundaries of cell therapy for cancer.

Learn more about us

Some of our partners

Latest news

Cartherics unveils new $4M lab to develop cancer immunotherapy treatments in Victoria

By Karen Loudon / October 13, 2022
MELBOURNE, Australia, 13 October 2022 – Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, has...
Read More

Cartherics granted first US patent for multiple development candidates

By Karen Loudon / October 6, 2022
Melbourne, Australia, 06 October 2022 – Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, announced...
Read More

Cartherics-led Consortium Receives $5.4M Federal Funding for Cellular Immunotherapy Research into Ovarian and Gastric Cancers

By Karen Loudon / September 30, 2022
MELBOURNE, Australia, 27 September 2022 – Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, together...
Read More